Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases
Yao, X.-Y.; Liu, W.; Li, Z.-Y.; Xiong, H.-L.; Su, Y.-Y.; Li, T.; Zhang, S.-Y.; Zhang, X.-J.; Bi, Z.-F.; Deng, C.-X.; Li, C.-Y.; Yuan, Q.; Zhang, J.; Zhang, T.-Y.; Wang, Z.-X.; Ge, S.-x.; Ningshao, X.
Show abstract
Knowledge of the host immune response after natural SARS-CoV-2 infection is essential for informing directions of vaccination and epidemiological control strategies against COVID-19. In this study, thirty-four COVID-19 patients were enrolled with 244 serial blood specimens (38.1% after hospital discharge) collected to explore the chronological evolution of neutralizing (NAb), total (TAb), IgM, IgG and IgA antibody in parallel. IgG titers reached a peak later (approximately 35 days postonset) than those of Nab, Ab, IgM and IgA (20[~]25 days postonset). After peaking, IgM levels declined with an estimated average half-life of 10.36 days, which was more rapid than those of IgA (51.25 days) and IgG (177.39 days). Based on these half-life data, we estimate that the median times for IgM, IgA and IgG to become seronegative are 4.59 (IQR 4.12-5.03), 7.78 (IQR 6.71-9.16) and 42.72 (IQR 33.75-47.96) months post disease onset. The relative contribution of IgM to NAb was higher than that of IgG (standardized {beta} regression coefficient: 0.53 vs 0.48), so the rapid decline in NAb may be attributed to the rapid decay of IgM in acute phase. However, the relative contribution of IgG to NAb increased and that of IgM further decreased after 6 weeks postonset. Its assumed that the decline rate of NAb might slow down to the same level as that of IgG over time. This study suggests that SARS-CoV-2 infection induces robust neutralizing and binding antibody responses in patients and that humoral immunity against SARS-CoV-2 acquired by infection may persist for a relatively long time.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Occurrence of COVID-19 symptoms during SARS-CoV-2 infection defines waning of humoral immunity 94%
- Upregulation of Activation Induced Cell Markers (AIM) among Severe COVID-19 patients in Bangladesh 93%
- Comparison of the mucosal and systemic antibody responses in Covid-19 recovered patients with one dose of mRNA vaccine and unexposed subjects with three doses of mRNA vaccines 93%
Similar papers in this journal
- Antibody response to SARS-CoV-2 infection in humans: a systematic review 93%
- Large-scale cross-sectional seroepidemiologic study of COVID-19 in Japan: Acquisition of herd immunity and the vaccines’ efficacy 93%
- Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders 93%
Similar papers in this journal
- Factors associated with the decay of anti-SARS-CoV-2 neutralizing antibodies among recipients of an adenoviral vector-based AZD1222 and a whole-virion inactivated (BBV152) vaccine in Chennai, India: a prospective, longitudinal, cohort study 93%
- Clinical significance of IgM and IgG test for diagnosis of highly suspected COVID-19 infection 92%
- Clinical findings in critical ill patients infected with SARS-Cov-2 in Guangdong Province, China: a multi-center, retrospective, observational study 91%
Similar papers in this journal
- SARS-CoV-2-induced humoral immunity through B cell epitope analysis and neutralizing activity in COVID-19 infected individuals in Japan 94%
- Dynamics of neutralizing antibody responses in acute-phase COVID-19: A potential relationship between disease progression and rapid neutralizing antibody response 93%
- The effect of ABO blood group and antibody class on the risk of COVID-19 infection and severity of clinical outcomes. 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.